Mineral-Homeostasis in Continuous Renal Replacement Therapy
Phosphate, Magnesium and Calcium-Homeostasis in Patients With Acute Renal Failure and Continuous Renal Replacement Therapy
Acute renal failure is a common complication in intensive care unit patients. In 10% of cases renal replacement therapy becomes necessary. Current devices have increase filter patency and efficacy. However, magnesium, calcium and phosphate are eliminated as well. However, the extend of this elimination hase not been quantified. Thus, we want to
- record retrospectively how often abnormal values for phosphate, magnesium and calcium occurred during routine renal replacement therapy in 2011 and 2012.
- prospectively evaluate the same parameters during routine treatment in 2013 and 2014
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Düsseldorf, Germany, 40225
- Interdisziplinäre Intensivstation Universitätsklinikum Düsseldorf
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- intensive care unit patients with acute renal failure undergoing continuous renal replacement therapy
- older than 18 years of age
Exclusion Criteria:
- age less than 18 years
- pregnancy
- contraindications against continuous renal replacement therapy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Retrospektive Cohort
Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
|
|
Prospektive Cohort
Patients requiring renal replacement on intensive care unit in 2013 and 2014
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of hypo-phosphate,-magnesium and calcaemia
Time Frame: approximately 28 days
|
Participants will be followed for the duration of ICU stay, an expected average of 28 days
|
approximately 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Detlef Kindgen-Milles, Prof., Department of Anaesthesiology, Duesseldorf University Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4209
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.